Resistant cytomegalovirus infection in related donor kidney allograft recipients

Goriaĭnov V.A.; Kaabak M.M.; Babenko N.N.; Platova E.N.; Aganesov A.G.; Morozova M.M.; Panin V.V.

doi:https://doi.org/10.17116/terarkh201688673-76

Goriaĭnov V.A.

Otdelenie transplantatsii pochki Rossiĭskogo nauchnogo tsentra khirurgii im. akad. B.V. Petrovskogo RAMN, Moskva

Kaabak M.M.

Otdelenie transplantatsii pochki Rossiĭskogo nauchnogo tsentra khirurgii im. akad. B.V. Petrovskogo RAMN, Moskva

Babenko N.N.

Otdelenie transplantatsii pochki Rossiĭskogo nauchnogo tsentra khirurgii im. akad. B.V. Petrovskogo RAMN, Moskva

Platova E.N.

acad. B.V. Petrovskiy Russian Research Surgery Center, Moscow

Aganesov A.G.

Rossiĭskiĭ nauchnyĭ tsentr khirurgii im. akad. B.V. Petrovskogo RAMN, Moskva

Morozova M.M.

Otdelenie khirurgii porokov serdtsa Rossiĭskogo nauchnogo tsentra khirurgii im. akad. B.V. Petrovskogo RAMN, Moskva

Panin V.V.

Laboratoriia klinicheskoĭ biokhimii Rossiĭskogo nauchnogo tsentra khirurgii im. akad. B.V. Petrovskogo RAMN, Moskva

Resistant cytomegalovirus infection in related donor kidney allograft recipients

Authors:

Goriaĭnov V.A., Kaabak M.M., Babenko N.N., Platova E.N., Aganesov A.G., Morozova M.M., Panin V.V.

More about the authors

Journal: Therapeutic Archive. 2016;88(6): 73‑76

DOI: 10.17116/terarkh201688673-76

Read: 1083 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Goriaĭnov VA, Kaabak MM, Babenko NN, Platova EN, Aganesov AG, Morozova MM, Panin VV. Resistant cytomegalovirus infection in related donor kidney allograft recipients. Therapeutic Archive. 2016;88(6):73‑76. (In Russ.)
https://doi.org/10.17116/terarkh201688673-76

Использование инфографики авторами научных работ

Close metadata

Abstract:

Aim. To clarify whether cytomegalovirus (CMV) infection can affect the results of living related donor kidney transplantation. Subjects and methods. A study group included 17 (7.27%) patients (10 men and 7 women; 8 children and 9 adults) aged 3 to 51 years who had developed resistant CMV infection. For comparative analysis, a control group was formed from 113 patients (61 men and 52 women; 40 children and 73 adults) aged 1 to 61 years, whose CMV polymerase chain reaction (PCR) had always been negative, i.e. CMV DNA was absent. The duration of CMV infection episodes was 44 to 232 days. Results. The patients were given valganciclovir in a dose of 450 mg/day. CMV PCR was negative in all the patients at the end of therapy. None of the patients died; one graft was lost. In the control (negative CMV PCR) group, 6 grafts were lost in 113 patients lost and 4 patients died. Statistical analysis showed that the results of related donor kidney transplantation were virtually equal. Conclusion. Suppression of resistant CMV infection can be achieved with the longer use of valganciclovir or its higher dose. CMV infection fails to affect the results of related donor kidney transplantation.

Keywords:

kidney transplantation

cytomegalovirus infection

antiviral therapy

Authors:

Goriaĭnov V.A.

Otdelenie transplantatsii pochki Rossiĭskogo nauchnogo tsentra khirurgii im. akad. B.V. Petrovskogo RAMN, Moskva

Kaabak M.M.

Otdelenie transplantatsii pochki Rossiĭskogo nauchnogo tsentra khirurgii im. akad. B.V. Petrovskogo RAMN, Moskva

Babenko N.N.

Otdelenie transplantatsii pochki Rossiĭskogo nauchnogo tsentra khirurgii im. akad. B.V. Petrovskogo RAMN, Moskva

Platova E.N.

acad. B.V. Petrovskiy Russian Research Surgery Center, Moscow

Aganesov A.G.

Rossiĭskiĭ nauchnyĭ tsentr khirurgii im. akad. B.V. Petrovskogo RAMN, Moskva

Morozova M.M.

Otdelenie khirurgii porokov serdtsa Rossiĭskogo nauchnogo tsentra khirurgii im. akad. B.V. Petrovskogo RAMN, Moskva

Panin V.V.

Laboratoriia klinicheskoĭ biokhimii Rossiĭskogo nauchnogo tsentra khirurgii im. akad. B.V. Petrovskogo RAMN, Moskva

Close metadata

References:

Kaabak M.M., Sandrikov V.A., Ragimov A.A. Analiz vyzhivaniya pochechnogo allotransplantata po dannym registra Rossiiskogo dializnogo obshchestva i vozmozhnye puti uluchsheniya otdalennykh rezul'tatov. Vestnik transplantologii i iskusstvennykh organov. 2006;4:31.
Goryainov V.A., Kaabak M.M., Molchanova E.A. Plazmaferez dlya lecheniya reperfuzionnoi travmy pri peresadke pochki. Vliyanie na blizhaishie i otdalennye rezul'taty. Vestnik Rossiiskoi akademii meditsinskikh nauk. 2002;5:43-45.
Kaabak M.M., Goryainov V.A., Zokoev A.K., Babenko N.N., Ragimov A.A., Salimov E.L., Solov'eva I.N., Alekseeva L.A., Morozova M.M., Shishlo L.A. Desyatiletnii opyt primeneniya rannego plazmafereza posle peresadki pochki. Vestnik transplantologii i iskusstvennykh organov. 2009;11(1):28-33.
Goryainov V.A., Kaabak M.M., Babenko N.N., Zokoev A.K., Morozova M.M., Shishlo L.A. Allotransplantatsiya rodstvennykh pochek u detei. Khirurgiya. Zhurnal im. N.I. Pirogova. 2008;6:58-62.
Kaabak MM, Babenko NN, Zokoev AK, Samsonov DV, Sandrikov VA, Maschan AA. Alemtuzumab induction in pediatric kidney transplantation. Pediatric Transplantation. 2013;17(2):168-178.
Balfour HH Jr, Chace DA. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med. 1989;320(21):1381.
Gane E, Saliba FM, Valdecassas GJ. Randomized trial of efficacy and safety og oral ganciclovir in the prevention cytomegalovirus disease in liver-transplant recipients. Lancet. 1997; 350(9093):1729.
Lowance D, Neumayer HH, Legendre CM. Valaciclovir for the prevention of cytomegalovirus disease after renal transplantation International Valaciclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med. 1999;340(19):1462.
Barkholt L, Lewensohn-Fuchs I, Ericzon BG. High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients. Transplant Infect Dis.1999;1(2):89.
Paya C, Humar A, Dominguez E. Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4:611.
Pescovitz M. Benefits of cytomegalovirus prophylaxis in solid organ transplantation. Transplantation. 2006:82:S4.
Pareyra L, Bruges M, Gaspar A et al. Prevention of cytomegalovirus disease in renal transplantation: single-center experience. Transpl Proc. 2009;41:877.
Leroy F, Secher A, Abou Ayache R, et al. Cytomegalovirus prophylaxis with intravenous polyvalent immunoglobulin in high-risk transplant recipients. Transplant Proc. 2006;38:2324.